ArticlePharmacoEconomics - open2026

Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan.

Kosuke Morimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.